ArticleTherapeutic advances in chronic disease2013
Treatment of autoimmune liver disease: current and future therapeutic options.
Article in Therapeutic advances in chronic disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Regulatory T cell therapy in autoimmune liver disease and transplantation.JHEP reports : innovation in hepatology · 2025Review
- A Case of Hepatitis in Pregnancy.Cureus · 2024Article
- Trends of autoimmune liver disease inpatient hospitalization and mortality from 2011 to 2017: A United States nationwide analysis.World journal of hepatology · 2024Article
- Prognostic factors for remission, relapse, and treatment complications in type 1 autoimmune hepatitis.Heliyon · 2020Article
- The Contribution of B Cells in Autoimmune Liver Diseases.Seminars in liver disease · 2019Review
- The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2018Article
- Therapeutic potential of phages in autoimmune liver diseases.Clinical and experimental immunology · 2018Review
- Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma.Journal of liver · 2018Article
- The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis.Hepatology communications · 2017Article
- Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases.Journal of immunology research · 2017Article
- Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.Frontline gastroenterology · 2016Article
- Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.Hepatology (Baltimore, Md.) · 2016Review
- Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.Molecular medicine reports · 2015Article
- Scaffold-mediated liver regeneration: A comprehensive exploration of current advances.Journal of tissue engineeringReview
- Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba.Current therapeutic research, clinical and experimentalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.